-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $5

Benzinga·06/30/2026 11:48:28
Listen to the news
Baird analyst Joel Beatty maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $7 to $5.